Clicky

Lipocine Inc.(LPCN) News

Date Title
Jun 27 Lipocine begins dosing in Phase III postpartum depression trial of LPCN 1154
Jun 26 Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression
Jun 23 Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025
Mar 13 Lipocine Announces Financial Results for the Full Year Ended December 31, 2024
Mar 12 Lipocine Announces FDA Labeling Changes for Testosterone Products
Oct 9 Lipocine signs supply and distribution agreement with Pharmalink for Tlando
Oct 8 Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries
Oct 2 Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
Aug 27 Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
Jun 25 Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
May 9 Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
May 8 Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
May 1 Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
Apr 11 Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Mar 28 Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
Mar 25 Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
Mar 7 Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
Mar 6 Lipocine to Present at 36th Annual Roth Conference
Feb 2 Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
Dec 19 Lipocine to Present at Biotech Showcase 2024